Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch

Developers have married gene-modulating oligonucleotides with the targeted precision of antibodies, and the first filings using such conjugates in Duchenne muscular dystrophy are imminent.

Author information Authors and Affiliations Dublin, Ireland

Cormac Sheridan

Rights and permissions About this article

Cite this article Sheridan, C. Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch.
Nat Biotechnol (2026). https://doi.org/10.1038/s41587-025-02987-0

Download citation

Published: 06 January 2026

Version of record: 06 January 2026

DOI : https://doi.org/10.1038/s41587-025-02987-0

Read whole article here